Comparative Study on Treatment of Facial Vitiligo
Published in Arch Dermatol Res. 2024 Jun 8;316(7):350
Loss and absence of melanocytes due to various factors lead to vitiligo, the most common pigmentation disorder. This study aimed to compare the effectiveness and safety of two treatments for facial vitiligo: excimer light with topical tacrolimus ointment 0.1% and excimer light with topical bimatoprost gel 0.01%.
48 patients with facial vitiligo participated in the study, with 24 patients in each treatment group. Clinical improvement based on the quartile grading scale at the end of treatment did not show any statistically significant difference between the two groups. The majority of subjects in both groups experienced good to excellent improvement. Only 20.9% of patients in the tacrolimus group and 33.3% in the bimatoprost group achieved less than 50% repigmentation (p = 0.889). The study demonstrated that 0.01% topical bimatoprost gel in combination with excimer light is considered safe and effective as a treatment for nonsegmental facial vitiligo with comparable results to 0.1% tacrolimus.
Value of Clinical Trials
Clinical trials are essential for developing safe and effective treatments. It’s crucial to translate their benefits into everyday medical practice. Our AI-driven platform, DocSym, consolidates ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians.
Practical Solutions for Healthcare
In today’s healthcare environment, streamlining operations is crucial. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally. By using AI, clinics can enhance their workflows, improve patient outcomes, and reduce paper routines. Learn more about how we can help at aidevmd.com.
